One of the final hurdles in front of Amgen's $28 billion acquisition of Horizon Pharma has fallen after an agreement was reached between the two companies and the Federal
Horizon Pharma's executive vice president, head of research and development, and chief scientific officer talks to pharmaphorum about what inspires her in life sciences,